Li Zhaoping, Yu Yue, Zhang Huanhuan, Xu Guifa, Chen Liyong
aDepartment of Nutrition, Shandong Provincial Hospital, Shandong University, Jinan bSchool of Public Health, Shandong University, Jinan, China.
Nucl Med Commun. 2015 Jul;36(7):695-701. doi: 10.1097/MNM.0000000000000302.
The purpose of this systematic meta-analysis was to evaluate the diagnostic accuracy of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for the assessment of glioma recurrence and compare it with that of (18)F-fluorodeoxyglucose ((18)F-FDG) PET.
The authors electronically and manually searched for studies from 1948 to 2014 that evaluated the diagnostic accuracy of (18)F-FDG or (18)F-FLT PET for glioma recurrence. The primary results of sensitivity, specificity, and diagnostic odds ratio (DOR) were summarized using the random-effects model. Summary receiver operating characteristic (ROC) curves and its area under the curve (AUC were used to summarize the overall diagnostic accuracy. Statistical analysis was performed with the software STATA (version 11.0).
Twenty-four studies that included a total of 799 patients were included in the meta-analysis. The pooled sensitivity, specificity, DOR, and summary ROC AUC for the overall diagnostic accuracy of (18)F-FDG PET were 0.78 (95% CI 0.69-0.85), 0.77 (95% CI 0.66-0.85), 12 (95% CI 6-22), and 0.84 (95% CI 0.81-0.87), respectively. The pooled sensitivity, specificity, DOR, and summary ROC AUC for the overall diagnostic accuracy of (18)F-FLT PET were 0.82 (95% CI 0.51-0.95), 0.76 (95% CI 0.50-0.91), 15 (95% CI 4-56), and 0.85 (95% CI 0.81-0.88), respectively. Metaregression analysis showed that year of publication, male proportion, average age, and blinding review did not affect the test performance statistically significantly (all P > 0.05).
This meta-analysis indicates that PET by using (18)F-FLT has a moderately better overall accuracy for diagnosing glioma recurrence compared with that by using (18)F-FDG. Video abstract: http://links.lww.com/NMC/A41.
本系统荟萃分析旨在评估3'-脱氧-3'-(18)F-氟胸腺嘧啶核苷((18)F-FLT)PET对胶质瘤复发评估的诊断准确性，并将其与(18)F-氟脱氧葡萄糖((18)F-FDG)PET的诊断准确性进行比较。
作者通过电子和手动检索1948年至2014年评估(18)F-FDG或(18)F-FLT PET对胶质瘤复发诊断准确性的研究。使用随机效应模型总结敏感性、特异性和诊断比值比(DOR)的主要结果。汇总的受试者工作特征(ROC)曲线及其曲线下面积(AUC)用于总结总体诊断准确性。使用STATA软件(版本11.0)进行统计分析。
荟萃分析纳入了24项研究，共799例患者。(18)F-FDG PET总体诊断准确性的汇总敏感性、特异性、DOR和汇总ROC AUC分别为0.78(95%CI 0.69 - 0.85)、0.77(95%CI 0.66 - 0.85)、12(95%CI 6 - 22)和0.84(95%CI 0.81 - 0.87)。(18)F-FLT PET总体诊断准确性的汇总敏感性、特异性、DOR和汇总ROC AUC分别为0.82(95%CI 0.51 - 0.95)、0.76(95%CI 0.50 - 0.91)、15(95%CI 4 - 56)和0.85(95%CI 0.81 - 0.88)。Meta回归分析显示，发表年份、男性比例、平均年龄和盲法审查对检测性能无统计学显著影响(所有P>0.05)。
本荟萃分析表明，与使用(18)F-FDG的PET相比，使用(18)F-FLT的PET在诊断胶质瘤复发方面总体准确性略高。视频摘要：http://links.lww.com/NMC/A41。
